DDInter1024 DDInter1658
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Lapatinib {u} (Compound) treats {v} (Disease) breast cancer
Lapatinib {u} (Compound) binds {v} (Gene) TAP1
Lapatinib {u} (Compound) upregulates {v} (Gene) VAV3
Lapatinib {u} (Compound) downregulates {v} (Gene) PLOD3
Lapatinib {u} (Compound) causes {v} (Side Effect) Nail disorder
Lapatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Lapatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Donepezil
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Propofol
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Lapatinib {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Lapatinib (Compound) treats breast cancer (Disease)
Lapatinib (Compound) binds TAP1 (Gene)
Lapatinib (Compound) upregulates VAV3 (Gene)
Lapatinib (Compound) downregulates PLOD3 (Gene)
Lapatinib (Compound) causes Nail disorder (Side Effect)
Lapatinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Lapatinib may cause a minor interaction that can limit clinical effects when taken with Donepezil
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Propofol
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Lapatinib may lead to a major life threatening interaction when taken with Macimorelin